AI-assisted, source-referenced information. Independent clinical review is pending. Our standards.
The short answer

Check the medicine, weekly strength, device and quantity together. Current UK Wegovy information includes a 7.2 mg option for some adults, so older advice calling 2.4 mg the universal maximum is incomplete.

The starting schedule builds gradually

The usual weekly escalation is 0.25, 0.5, 1 and 1.7 mg, spending four weeks at each step before 2.4 mg. Significant digestive symptoms can require the prescriber to reconsider the timing. Do not accelerate the schedule because you have bought several strengths or because the early effect seems modest.

When your prescription changes, compare the label with the written plan before injecting. Keep the old and new boxes clearly identifiable. Ask the pharmacist to explain an unfamiliar device rather than assuming every semaglutide pen works in the same way.

Sources: Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: UK Summary of Product Characteristics; Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: patient information leaflet

What changed with 7.2 mg

The MHRA authorised a higher weekly dose for adults with obesity. The current product information allows consideration of 7.2 mg after at least four weeks on 2.4 mg when needed. It is not a routine dose for every person with overweight, and doses above 2.4 mg are not recommended for adolescents under the weight-management schedule.

This changes how a price should be read. A quote for a 2.4 mg pen is not necessarily a quote for a complete 7.2 mg weekly regimen. Ask the dispensing service to identify the exact product and the intended supply period. The prescriber should explain why the higher option is being considered and how benefit and tolerability will be reviewed.

Sources: MHRA: MHRA approves up to 7.2 mg semaglutide for adults with obesity; Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: UK Summary of Product Characteristics

The device determines the instructions

The current UK information describes more than one way of supplying a 7.2 mg dose, depending on the device. This is a reason to obtain a demonstration or clear pharmacist guidance for the product actually dispensed. An internet video showing a different pen may be accurate for that pen and still be wrong for yours.

Confirm the dose display, the number of doses in the supplied pack, needle arrangements and sharps disposal. Do not count clicks to manufacture a different dose or combine products from separate prescriptions. If you are unsure whether an injection was completed, ask for advice before repeating it; uncertainty is not a reason to give an extra dose.

Sources: Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: patient information leaflet; Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: UK Summary of Product Characteristics

Keep missed-dose and restart questions separate

The injection leaflet allows a missed dose within five days; after that, it is skipped and the next dose is taken on the usual day. A longer gap may need a different restart approach. Do not apply a tablet's missed-dose rule to a weekly injection, and do not use another GLP-1 medicine's timing rule.

When requesting help, provide the last actual dose and the usual injection day. If a prescription delay caused the gap, tell the provider before placing a repeat order. The practical aim is to have the restart decision and the supply arranged together.

Sources: Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: patient information leaflet

Ask what the next review will decide

A dose review should connect treatment response with tolerability and health goals. STEP UP found greater average weight loss with 7.2 mg than 2.4 mg under its study conditions, but the higher result does not decide the trade-off for you. Explain which symptoms or practical problems would make continuing difficult.

Keep a simple record of injection dates and questions. Ask when the service expects the next assessment and who to contact if problems arise sooner. The strength printed on a pen is a prescription detail; it is not a score of how well you are doing.

Sources: The Lancet Diabetes & Endocrinology / PubMed: STEP UP: Once-weekly semaglutide 7.2 mg in adults with obesity; NICE: Overweight and obesity management: medicines and surgery

Questions, answered.

Can I use an old video to learn a new pen?

Use the instructions for the exact device supplied, and ask the pharmacist to demonstrate anything unclear. Different devices may have different steps.

Sources: Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: patient information leaflet

Should I order 7.2 mg because it is now authorised?

Only if your prescriber has assessed it as appropriate and supplied a specific plan. Authorisation creates an option, not an instruction for everyone.

Sources: MHRA: MHRA approves up to 7.2 mg semaglutide for adults with obesity

Sources & further reading

Original sources for this guide. Source checks are not independent clinical review.

  1. Wegovy FlexTouch: UK Summary of Product CharacteristicsNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
  2. Wegovy FlexTouch: patient information leafletNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
  3. MHRA approves up to 7.2 mg semaglutide for adults with obesityMHRA · Accessed 19 November 2026
  4. STEP UP: Once-weekly semaglutide 7.2 mg in adults with obesityThe Lancet Diabetes & Endocrinology / PubMed · Accessed 19 November 2026
  5. Overweight and obesity management: medicines and surgeryNICE · Accessed 19 November 2026